Structural Formula (Gemcitabine Injection 1)
Gemcitabine Injection, Solution
Product Images NDC 0143-9342
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 0143-9342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Gemcitabine Injection 2)
Not available.*
Figure 2 (Gemcitabine Injection 3)
This text provides data on the progression-free probability of patients receiving Gemcitabine/Paclitaxel compared to Paclitaxel alone. The median time to documented disease progression was 5.2 months for Gemcitabine/Paclitaxel and 2.9 months for Paclitaxel alone. The statistical analysis showed a significant difference between the two groups with a p-value of less than 0.0001. The chart displays the progression-free probability over time for both treatment groups.*
Figure 3 (Gemcitabine Injection 4)
This text provides survival data for patients who received Gemcitabine/Cisplatin and Cisplatin treatment. The median survival for Gem/Cis was 9.0 months with a 1-year survival rate of 39%, while for Cisplatin, the median survival was 7.6 months with a 1-year survival rate of 28%. Test statistics such as Logrank (p=0.008) and Wilcoxon (p=0.018) are provided for comparison. The study included 260 patients in the Gemcitabine/Cisplatin group and 262 patients in the Cisplatin group for evaluating survival time in months.*
Image Of Figure 4 (Gemcitabine Injection 5)
This text provides data on the fraction surviving at different time points, as well as survival times for 5-FU and Gemcitabine treatments in months. The information can be used to analyze and compare the efficacy of these treatments in terms of patient survival rates.*
Gemcitabine 200mg Vial (Gemcitabine Injection 6)
This is a product label providing information about a medication containing 200 mg of gemcitabine. The medication is in an injection form and comes in a single-dose vial of 5.26 mL. The label also indicates to discard any unused portions of the medication. This product is for prescription use only.*
Gemcitabine 1g Vial (Gemcitabine Injection 7)
This is a product label for gemcitabine injection, a cytotoxic agent used for intravenous infusion only. Each single-dose vial contains 1g of gemcitabine to be diluted before use. The storage instructions suggest keeping it at 2°C to 8°C. The product is manufactured by Thymoorgan Pharmazie GmbH in Germany and distributed by Hikma in Berkeley Heights, New Jersey.*
Gemcitabine 2g Vial (Gemcitabine Injection 8)
This is a description of a vial of gemcitabine, a cytotoxic agent used for injection. The vial contains 2.227 grams of gemcitabine and must be diluted before intravenous infusion. It should be stored at 2° to 8°C. The product is manufactured by THYMOORGAN PHARMAZIE in Germany and distributed by a company located in Berkeley Heights, NJ. Unused potion should be discarded. Dosing and administration instructions can be found in the package insert.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
